COMPANY
Oblato
Timeline
- Trial start Phase 1: Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma source ↗
- Trial start Phase 1/Phase 2: Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants source ↗
- Trial start Phase 2: Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma source ↗
- Trial start Phase 1: Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients source ↗
Clinical trials (lead sponsor) 5
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04388475 | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | Phase 2 | Completed | Jun 12, 2020 | May 8, 2024 (actual) |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | Phase 1 | Active, not recruiting | Apr 17, 2023 | May 31, 2025 (estimated) |
| NCT05518838 | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | Not listed | No longer available | Not listed | Not listed |
| NCT01672463 | Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients | Phase 1 | Unknown status (ClinicalTrials.gov) | 2012-12 | Jan 31, 2023 (actual) |
| NCT03649464 | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants | Phase 1/Phase 2 | Withdrawn | 2022-08 | 2025-04 (estimated) |